Skip to main content
main-content

Onkologie und Hämatologie | Zeitschrift

memo - Magazine of European Medical Oncology

memo - Magazine of European Medical Oncology 4/2019

Ausgabe 4/2019

Inhaltsverzeichnis ( 19 Artikel )

01.12.2019 | editorial | Ausgabe 4/2019

An update from the 2019 ASCO Annual Meeting

Rupert Bartsch

01.12.2019 | editorial | Ausgabe 4/2019

Amazing advances in the field of uro-oncology

Dora Niedersüß-Beke

01.12.2019 | editorial | Ausgabe 4/2019

Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?

Rupert Bartsch

06.11.2019 | original report | Ausgabe 4/2019 Open Access

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

A cross-sectional multicentre observational study
Assoc. Prof. Marija Balic MDPhD, Wolfgang Hilbe, Sylvia Gusel, Michael Fiegl, Heinz Ludwig, Beate Mayrbäurl, Josef Thaler, Hellmut Samonigg, Karin Hegenbarth, Florian Eisner, Brigitte Mlineritsch, Richard Greil, Maria Johanna Schandl, Ansgar Weltermann, Andreas Petzer, David Fuchs, Wolfgang Stangl, Peter Krippl, Reinhard Stauder, Herbert Stöger

06.11.2019 | short review | Ausgabe 4/2019

Current trends in small cell lung cancer management—ASCO 2019 update

Mircea Dediu MD, PhD

06.11.2019 | short review | Ausgabe 4/2019 Open Access

Targeted therapy in lung cancer—ASCO 2019 update

Romana E. Wass M.D., Ph.D., David Lang M.D., Bernd Lamprecht M.D., Michael Studnicka M.D.

21.11.2019 | short review | Ausgabe 4/2019

ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

Prof. Semir Beslija MD, PhD

12.11.2019 | review | Ausgabe 4/2019 Open Access

ASCO 2019: highlights in HER2-positive metastatic breast cancer

Rupert Bartsch, Elisabeth Bergen

15.10.2019 | short review | Ausgabe 4/2019 Open Access

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

The best of ASCO 2019
Christoph Suppan, Marija Balic

14.11.2019 | short review | Ausgabe 4/2019

Management of nonmetastatic muscle invasive bladder cancer in the elderly

Prof. Stephan Madersbacher MD, FEBU

27.09.2019 | short review | Ausgabe 4/2019 Open Access

Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?

Stephan Brönimann, Shahrokh F. Shariat, Melanie R. Hassler

28.10.2019 | short review | Ausgabe 4/2019

Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract

Presentation highlights from the ASCO 2019 Congress
Assoc. Prof. Georg C. Hutterer MD, Assoc. Prof. Martin Pichler MD

23.10.2019 | short review | Ausgabe 4/2019 Open Access

Neoadjuvant therapy in urothelial cancer

New therapies on the horizon
Stephan Brönimann, David D’Andrea, Shahrokh F. Shariat, Kilian M. Gust MD

21.11.2019 | short review | Ausgabe 4/2019

First-line treatment of metastatic renal cell carcinoma: current standard of care

Assoc. Prof. Martin Marszalek MD

14.11.2019 | short review | Ausgabe 4/2019

Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?

Ursula Vogl MD

28.11.2019 | short review | Ausgabe 4/2019

Biomarkers in renal cell carcinoma

OÄ. Dr. Jasmin Terzic, Univ.-Prof. Dr. med. univ. Thomas Bauernhofer

21.11.2019 | short review | Ausgabe 4/2019

Surgery in renal cell carcinoma—when, whom and how?

Sebastian Lenart MD, Ingrid Berger, Nikolaus Hartig, Stephan Madersbacher, Anton Ponholzer

27.11.2019 | short review | Ausgabe 4/2019 Open Access

HPV-associated cancers

Dr. Christoph Minichsdorfer PhD

26.06.2019 | case report | Ausgabe 4/2019

Giant leiomyoma of the renal capsule: CT and MR imaging features with pathologic correlations

Arnaldo Stanzione, Michele Santangelo, Filippo De Rosa, Andrea Ponsiglione, Gaia Peluso, Luigi Insabato, Massimo Imbriaco MD

Aktuelle Ausgaben